10.23.14
NutraGenesis, LLC lauded the publication of a new study on AllerGuard Express, which demonstrated AllerGuard Express’s ability to provide superior respiratory wellness benefits in a fast-acting, experiential manner.
In a recent, 2‐arm crossover human clinical trial published in the peer reviewed Food Science and Nutrition Journal, subjects were exposed to a standardized amount of a mixture of outdoor and indoor allergens (including grass and tree pollen, dust mites, and animal dander) and then immediately took two tablets of either AllerGuard Express or placebo when symptoms began to develop.
The ability to breathe through their nose over the next two hours was determined at 15‐minute intervals using a mechanical device that measured precisely their level of Peak Nasal Inspiratory Flow (PNIF).
Subjects also reported their subjective perception of how they felt in terms of allergy-related symptoms (stuffy nose, runny nose, itchy nose, watery eyes, and itchy eyes) using Visual Analog Scales (VAS). After a washout period, the subjects repeated the testing using the alternative treatment.
Subjects experienced improved nasal breathing and enhanced feeling of wellness throughout the evaluation period, beginning as soon as 15 minutes after consumption of AllerGuard Express.
This illustrates AllerGuard Express’ unique, fast-acting benefits. After 15 minutes, there was a 27.7% reduction in PNIF score in the group taking AllerGuard Express (indicating an enhanced ability to breathe through the nose) and an improvement in subjects’ perception of allergy-related symptoms ranging from 12-30%. Runny nose in the AllerGuard Express group improved by 60% compared to placebo by the end of the 2-hour evaluation period. In this study AllerGuard Express was found to be highly bioavailable and well tolerated.
For more information: www.nutragenesis.com
In a recent, 2‐arm crossover human clinical trial published in the peer reviewed Food Science and Nutrition Journal, subjects were exposed to a standardized amount of a mixture of outdoor and indoor allergens (including grass and tree pollen, dust mites, and animal dander) and then immediately took two tablets of either AllerGuard Express or placebo when symptoms began to develop.
The ability to breathe through their nose over the next two hours was determined at 15‐minute intervals using a mechanical device that measured precisely their level of Peak Nasal Inspiratory Flow (PNIF).
Subjects also reported their subjective perception of how they felt in terms of allergy-related symptoms (stuffy nose, runny nose, itchy nose, watery eyes, and itchy eyes) using Visual Analog Scales (VAS). After a washout period, the subjects repeated the testing using the alternative treatment.
Subjects experienced improved nasal breathing and enhanced feeling of wellness throughout the evaluation period, beginning as soon as 15 minutes after consumption of AllerGuard Express.
This illustrates AllerGuard Express’ unique, fast-acting benefits. After 15 minutes, there was a 27.7% reduction in PNIF score in the group taking AllerGuard Express (indicating an enhanced ability to breathe through the nose) and an improvement in subjects’ perception of allergy-related symptoms ranging from 12-30%. Runny nose in the AllerGuard Express group improved by 60% compared to placebo by the end of the 2-hour evaluation period. In this study AllerGuard Express was found to be highly bioavailable and well tolerated.
For more information: www.nutragenesis.com